Molecular Structure of an Unexpected Binuclear Salicylaldimine Semicarbazone Palladium(II) Complex

Abstract  

Reaction of a salicylaldehyde semicarbazone ligand with PdCl₂(PPh₃)₂ yields an unexpected binuclear Pd(II) complex, 2. The complex crystallizes in a triclinic system with a P-1 space group, with unit cell parameters a = 14.0283(3) ?, b = 15.2603(3) ?, c = 18.7142(3) ?, α = 66.662(10)°, β = 86.162(10)°, γ = 76.265(10)°, Z = 2. The semicarbazone ligand acts as a tridentate chelating donor to one palladium metal centre, forming a five- and six- membered ring, and a monodentate donor to the second palladium centre. There are four molecules of solvent per complex molecule in the asymmetric unit. Each metal centre is contained within a slightly distorted square-planar environment.     

Immediate release tablets of telmisartan using superdisintegrant-formulation, evaluation and stability studies

Telmisartan (anti-hypertensive) is insoluble in water; hence the drug may be slowly or incompletely dissolved in the gastro intestinal tract. So the rate of dissolution and therefore its bioavailability is less (bioavailability 42%). In the present study an attempt has been made to prepare immediate release tablets of telmisartan by using Polyplasdone XL-10 (Crosspovidone) at intragranular, extragranular and partly intra and extragranular level of addition to increase the rate of drug release from dosage form to increase the dissolution rate and hence its bioavailability. The prepared granules and tablets were evaluated for their physiochemical properties and in-vitro dissolution study was conducted for the prepared tablets. It was concluded that the immediate release tablets with proper hardness, disintegration time and with increase rate of dissolution can be made using Polyplasdone XL-10. Formuation-10 (F10) was selected for stability study and the in-vitro dissolution study showed that was no difference in percent of drug released between initial and sixth month sample.     

Enhancing the Activity of Drugs by Conjugation to Organometallic Fragments

Resistance to chemotherapy is a current clinical problem, especially in the treatment of microbial infections and cancer. One strategy to overcome this is to make new derivatives of existing drugs by conjugation to organometallic fragments, either by an appropriate linker, or by direct coordination of the drug to a metal. We illustrate this with examples of conjugated organometallic metallocene sandwich and half-sandwich complexes, Ru^II and Os^II arene, and Rh^III and Ir^III cyclopentadienyl half-sandwich complexes. Ferrocene conjugates are particularly promising. The ferrocene–chloroquine conjugate ferroquine is in clinical trials for malaria treatment, and a ferrocene-tamoxifen derivative (a ferrocifen) seems likely to enter anticancer trails soon. Several other examples illustrate that organometallic conjugation can restore the activity of drugs to which resistance has developed.     

Synthesis and structural characterization of binuclear palladium(II) complexes of salicylaldimine dithiosemicarbazones

A series of binuclear palladium(II) salicylaldiminato dithiosemicarbazone complexes have been synthesized and characterized. The palladium complexes were obtained by the reaction of various ethylene- and phenylene-bridged dithiosemicarbazones with Pd(PPh₃)₂Cl₂. The free salicylaldimine ligands and their palladium complexes were characterized by NMR and IR spectroscopies, ESI-mass spectrometry, elemental analyses and for two representative complexes also by X-ray diffraction. In both metal complexes, the solid-state structures show the two palladium centers to be coordinated in a slightly distorted square-planar geometry, which gives rise in each case to five- and six-membered chelate rings. The salicylaldimine thiosemicarbazone ligands coordinate to palladium in a tridentate manner, through the phenolic oxygen, imine nitrogen and thiolate sulfur atoms.     

The Implication of Low Dose Dimethyl Sulfoxide on Mitochondrial Function and Oxidative Damage in Cultured Cardiac and Cancer Cells

Although numerous studies have demonstrated the biological and multifaceted nature of dimethyl sulfoxide (DMSO) across different in vitro models, the direct effect of “non-toxic” low DMSO doses on cardiac and cancer cells has not been clearly explored. In the present study, H9c2 cardiomyoblasts and MCF-7 breast cancer cells were treated with varying concentrations of DMSO (0.001–3.7%) for 6 days. Here, DMSO doses < 0.5% enhanced the cardiomyoblasts respiratory control ratio and cellular viability relative to the control cells. However, 3.7% DMSO exposure enhanced the rate of apoptosis, which was driven by mitochondrial dysfunction and oxidative stress in the cardiomyoblasts. Additionally, in the cancer cells, DMSO (≥0.009) led to a reduction in the cell’s maximal respiratory capacity and ATP-linked respiration and turnover. As a result, the reduced bioenergetics accelerated ROS production whilst increasing early and late apoptosis in these cells. Surprisingly, 0.001% DMSO exposure led to a significant increase in the cancer cells proliferative activity. The latter, therefore, suggests that the use of DMSO, as a solvent or therapeutic compound, should be applied with caution in the cancer cells. Paradoxically, in the cardiomyoblasts, the application of DMSO (≤0.5%) demonstrated no cytotoxic or overt therapeutic benefits.     

An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting

The colon specific drug delivery systems based on polysaccharides; locust bean gum and chitosan in the ratio of 2 : 3, 3 : 2 and 4 : 1 were evaluated using in vitro and in vivo methods. The in vitro studies in pH 6.8 phosphate buffer containing 2% w/v rat caecal contents showed that the cumulative percentage release of mesalazine after 26 h were 31.25+/-0.56, 46.25+/-0.96, 97.5+/-0.26 (mean+/-S.D.), respectively. The in vivo studies conducted in nine healthy male human volunteers for the various formulations revealed that, the drug release was initiated only after 5 h (i.e.) transit time of small intestine and the bioavailability (AUC(0-->t*)) of the drug was found to be 85.24+/-0.10, 196.08+/-0.12, 498.62+/-0.10 microg x h/ml 26 (mean+/-S.D.), respectively. These studies on the polysaccharides demonstrated that the combination of locust bean gum and chitosan as a coating material proved capable of protecting the core tablet containing mesalazine during the condition mimicking mouth to colon transit. In particular, the formulation containing locust bean gum and chitosan in the ratio of 4 : 1 held a better dissolution profile, higher bioavailability and hence a potential carrier for drug targeting to colon.     

Thiosemicarbazone salicylaldiminato palladium(II)-catalyzed alkynylation couplings between arylboronic acids and alkynes or alkynyl carboxylic acids

An efficient catalytic system has been developed for the synthesis of unsymmetrical substituted alkynes via the thiosemicarbazone salicylaldiminato palladium(II)-catalyzed alkynylation couplings between arylboronic acids and alkynes or alkynyl carboxylic acids under mild conditions.